Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Folinic Acid: Supplementation and Therapy (FAST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02810275
Recruitment Status : Completed
First Posted : June 22, 2016
Last Update Posted : November 30, 2016
Sponsor:
Collaborator:
Universidade Federal de Santa Maria
Information provided by (Responsible Party):
Sandra Costa Fuchs, Hospital de Clinicas de Porto Alegre

Brief Summary:

Patients infected by HIV or HIV-HCV coinfected have higher survival due to the use of HAART, but survival is accompanied by increased morbidity and associated cardiovascular disease (CVD). Endothelial dysfunction is an early marker of atherogenesis, acting as an intermediate in the causal pathway of CVD. Folinic acid (FA) has been shown to reduce CVD outcomes, especially among individuals with hyperhomocisteinemia.

To date, few studies provided consistent information about efficacy of pharmacological interventions that minimize damage to the vascular endothelium in patients infected by HIV or HIV-HCV coinfected. The main hypothesis of this study is that FA supplementation protects the vascular endothelium, and consequently might prevent subclinical atherosclerosis. Thus, the first step is to determine the efficacy of supplementation with FA, and to compare the effect between HIV and HIV-HCV coinfected.


Condition or disease Intervention/treatment Phase
HIV Infection HCV Coinfection Drug: Folinic Acid Drug: Placebo Phase 3

Detailed Description:

Study design: This was a randomized placebo-controlled trial, with blinding of health care team, participants, and investigators, in which the participants were randomly assigned in a 1:1 ratio to receive FA or placebo for four weeks.

Participants: Patients receiving care for HIV, at the outpatient clinic of the Hospital Universitario de Santa Maria, in southern Brazil, from October 2012 to September 2013, were recruited. Eligible participants: HIV infected or HIV-HCV coinfected patients, 18-50 years, men and women, receiving HAART, had undetectable viral load for more than six months. Patients were excluded: patients with diabetes mellitus, previous acute myocardial infarction, myocardial revascularization, or stroke, creatinine >1.5 mg/dL, clinical diagnosis or ultrasound, endoscopic, or laboratory evidence of liver cirrhosis, on treatment with statins, fibrates, hormone replacement therapy, sulfonamides, vitamin supplements, or FA in the last 30 days, and pregnant women.

Intervention Patients assigned to the intervention group received FA 5 mg, per oral, once a day, in the morning, during four weeks. Patients assigned to the placebo group received the same prescription. The trial provided FA and placebo in tablet form, identical in color, smell, taste, shape, and size. Both FA and placebo were prepared in a single batch, in an independent laboratory, by a pharmacist with no involvement in the trial. They were pre-packed in bottles containing 30 tablets each, individually labeled with an alphanumeric code and stored.

Outcomes The primary endpoint were changes in homocysteine, vitamin B12 levels, and brachial artery FMD during reactive hyperemia, as measured by Doppler ultrasound, from randomization to the end of follow-up. FMD was characterized by the variation in mean arterial flow measured as the peak change in vessel diameters relative to the baseline.

Sample size Sample size was calculated based on the results of a previous RCT,(14) which used plethysmography to measure FMD. To detect a difference of at least 6% between intervention and placebo groups, with standard deviations ranging from 5% to 7%, we calculated that a sample size of at least 17 patients per group, with randomization stratified by HCV coinfection status, was required to achieve 80% power and a 95% confidence interval.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 69 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Effect of Folic Acid on Homocysteine Levels and Flow-mediated Dilation in HIV and HIV-HCV Coinfected Patients: a Randomized Controlled Trial
Study Start Date : October 2012
Actual Primary Completion Date : July 2013
Actual Study Completion Date : September 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Folic Acid HIV/AIDS

Arm Intervention/treatment
Experimental: Folinic Acid
Folinic acid group received 5 mg daily during four weeks
Drug: Folinic Acid
Folinic acid 5 mg, taking in the morning, daily, during four weeks
Other Name: FA

Placebo Comparator: Placebo
Placebo group received a tablet daily during four weeks
Drug: Placebo
Placebo capsule received 1 tablet, taking in the morning, during four weeks
Other Name: Control




Primary Outcome Measures :
  1. Flow mediated dilatation [ Time Frame: Four weeks ]
    The response was defined by the variation in the flow mediated dilatation between intervention and placebo groups.


Secondary Outcome Measures :
  1. Serum homocysteine [ Time Frame: Four weeks ]
    Variation in the serum homocysteine between intervention and placebo groups.


Other Outcome Measures:
  1. Blood pressure [ Time Frame: Four weeks ]
    The response was defined by variation in blood pressure between intervention and placebo groups.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • HIV infected patients
  • HIV-HCV coinfected patients
  • 18-50 years
  • men and women
  • receiving HAART
  • with undetectable viral load for more than six months.

Exclusion Criteria:

  • Patients with diabetes mellitus,
  • previous CVD: acute myocardial infarction, myocardial revascularization, or stroke,
  • creatinine >1.5 mg/dL,
  • clinical diagnosis or ultrasound, endoscopic, or laboratory evidence of liver cirrhosis,
  • on treatment with: statins, fibrates, hormone replacement therapy, sulfonamides, vitamin supplements, or FA in the last 30 days,
  • pregnant women.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02810275


Sponsors and Collaborators
Hospital de Clinicas de Porto Alegre
Universidade Federal de Santa Maria
Investigators
Layout table for investigator information
Study Chair: Sandra C Fuchs, PhD, MD Hospital de Clinicas de Porto Alegre
Layout table for additonal information
Responsible Party: Sandra Costa Fuchs, Full Professor, Hospital de Clinicas de Porto Alegre
ClinicalTrials.gov Identifier: NCT02810275    
Other Study ID Numbers: CAAE: 00533612.8.0000.5346
GPPG-140240 ( Other Grant/Funding Number: Hospital de Clinicas de Porto Alegre - FIPE )
RBR-9366qc ( Registry Identifier: Brazilian Clinical Trials Registry (ReBEC) )
First Posted: June 22, 2016    Key Record Dates
Last Update Posted: November 30, 2016
Last Verified: September 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Coinfection
Virus Diseases
Infection
Parasitic Diseases
Leucovorin
Folic Acid
Levoleucovorin
Antidotes
Protective Agents
Physiological Effects of Drugs
Vitamin B Complex
Vitamins
Micronutrients
Nutrients
Growth Substances
Hematinics